9 results about "LRP6" patented technology

The invention relates to the technical field of molecular biology, in particular to siRNA for interfering LRP6 as well as a product and application thereof. The nucleotide sequence of the siRNA for interfering with the LRP6 is shown as SEQ ID NO.1-8. The invention also discloses a preparation method of the siRNA. After an interference fragment of the LRP6 is obtained through screening, cell transfection is carried out, the LRP6 is interfered through siRNA, it is revealed that the interference LRP6 significantly inhibits the activity of subpigskin precursor fat cells and promotes differentiation and adipogenesis of the subpigskin precursor fat cells, it is revealed that the LRP6 can positively regulate and control proliferation of the subpigskin precursor fat cells and negatively regulate and control adipogenesis, a reference is provided for optimizing the pig fat deposition efficiency, and the application of the LRP6 in the field of pig fat deposition is provided. Effective functional genes are provided for pork quality character breeding, and effective targets are provided for high-quality pork pigs.

The application discloses a kind of nanobody specifically binding LRP5 and / or 6 and its application.The nanobody has the ability of selectively targeting and binding LRP5 and / or LRP6, wherein part of the antibody can inhibit the interaction of LRP5 and / or LRP6 with Wnt protein, thereby effectively inhibiting Wnt signaling pathway.The nanobody provided by the application can not only specifically recognize the co-receptor LRP5 and / or LRP6 of Wnt signaling pathway, but also show higher binding affinity, and can be widely applied in the detection of LRP5 and / or LRP6 and related research fields.

Disclosed are a nanobody that specifically binds to LRP5 and / or LRP6 and a use thereof. The nanobody has the ability to selectively target and bind to LRP5 and / or LRP6. Some antibodies can inhibit the interaction between LRP5 and / or LRP6 and Wnt proteins, thereby effectively suppressing the Wnt signaling pathway. The provided nanobody specifically recognizes co-receptors LRP5 and / or LRP6 of the Wnt signaling pathway, exhibits high binding affinity, and can be widely applied to the field of detection and related research of LRP5 and / or LRP6.

The application belongs to the field of biological medicine, and discloses application of YTHDF3 in preparation of products for diagnosing and treating cervical cancer. Specifically disclosed are: application of YTHDF3 as a biomarker in preparation of reagents for diagnosing cervical cancer and lymph node metastasis of cervical cancer; application of YTHDF3 protein in preparation of a prognostic evaluation kit for cervical cancer, the kit taking the above protein as a prognostic evaluation marker; a drug for treating cervical cancer, including any one of a drug capable of specifically inhibiting SREBF1 gene or protein, a drug capable of specifically inhibiting YTHDF3 gene or protein, a drug for inhibiting translation of an m6A modified transcript of LRP6, and a drug for inhibiting proliferation, migration and invasion of cervical cancer cells. The above products are used for diagnosing and treating cervical cancer, and have good specificity. In addition, YTHDF3 can promote lymph node metastasis of cervical cancer, so products taking the molecule as a marker can effectively treat cervical cancer with lymph node metastasis.

The invention provides an application of an STT3A gene inhibitor in treatment of RSPO and / or RNF43 / ZNRF3 gene mutation type cancers. The STT3A gene inhibitor can be used for treating the RSPO and / or RNF43 / ZNRF3 gene mutation type cancers. Specifically, the STT3A gene inhibitor can inhibit N-glycosylation modification of LRP6, so that abnormal activation of a Wnt pathway caused by RSPO and / or RNF43 / ZNRF3 gene mutation is inhibited, and cancers caused by abnormal activation of the Wnt pathway are treated. In addition, the invention also provides a pharmaceutical composition and a treatment method for treating RSPO and / or RNF43 / ZNRF3 gene mutant cancers.

The invention discloses a shark source single-domain antibody targeting LRP6 and application of the shark source single-domain antibody. The single-domain antibody has an amino acid sequence as shown in SEQ ID NO: 1, shows nanomole-level high affinity to LRP6 protein, has an affinity constant KD value of 1.8 * 10 <-9 > M, shows excellent physical and chemical stability, has a thermal denaturation temperature as high as 75.6 DEG C, and can still retain 92% or more of binding activity after being incubated for 2 hours under a strong acidic condition. Meanwhile, the antibody has high specificity, and the cross reaction rate of the antibody with homologous protein LRP5 and homologous protein LDLR is lower than 4%. The invention also provides a composition for reducing hypertension, hyperglycemia and hyperlipidemia, which contains the single-domain antibody and a specific natural plant extract composite component. Experiments show that the composition can synergistically act on a plurality of pathological links of the metabolic syndrome, the symptoms of hyperglycemia, hyperlipidemia and hypertension are remarkably improved in an animal model, the effect is better than that of a single component and a traditional control drug, and a brand new multi-target treatment scheme is provided for prevention and treatment of the metabolic syndrome.

To provide a method for treating gastrointestinal disorders using a modified WNT agonist and a modulator of the WNT signaling pathway. [Solution] In one embodiment, the present disclosure includes an engineered WNT agonist comprising (a) one or more binding domains that bind to one or more FZDs; and (b) one or more binding domains that bind to LRP5, LRP6, or both LRP5 and LRP6, wherein the polypeptide sequence has at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to any of SEQ ID NOs: 1 to 18, or a polypeptide sequence disclosed in any one of SEQ ID NOs: 1 to 25, Figure 2, Figure 6, Table 1, or Table 3, or a functional fragment or variant thereof, for example, its binding fragment, for example, a VHH domain, a heavy chain variable domain, or a light chain variable domain.